Abstract
<h3>In Reply.</h3> —Dr Orr questions the use of a placebo period described in the selected patient who was reported in our article. This patient participated in a carefully controlled, prospective, double-blind treatment trial with the then-experimental and atypical antipsychotic clozapine.<sup>1</sup>This study resulted in the first non—industry-supported data indicating the superiority of clozapine in comparison with a representative traditional antipsychotic. Informed written consent was required prior to entry into the study; the patient's continuing assent and understanding of experimental procedures were monitored regularly throughout the study. Withdrawal of consent at any time and for any reason is justification for termination of participation. The inclusion of a placebo period in the crossover design enabled biological and clinical investigation into the effects of clozapine with minimal contamination by prior drug treatment. This approach led to a number of observations pertaining to the mechanism of action and clinical effectiveness of clozapine.<sup>2,3</sup>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
